Abstract Coronavirus Disease 2019 (COVID-19) has been the most severe public health
challenge in this century. Two years after its emergence, the rapid development and …

Background The efficacy of SARS-CoV-2 vaccines in preventing severe COVID-19 illness
and death is uncertain due to the rarity of data in individual trials. How well the antibody …

Background The safety, reactogenicity, immunogenicity, and efficacy of the mRNA-1273
coronavirus disease 2019 (Covid-19) vaccine in young children are unknown. Methods Part …

Abstract mRNA vaccines have emerged as highly effective strategies in the prophylaxis and
treatment of diseases, thanks largely although not totally to their extraordinary performance …

At present, there are more than 560 million confirmed cases of the coronavirus disease 2019
(COVID-19) worldwide. Although more than 98% of patients with severe acute respiratory …

Importance Evidence of the efficacy and safety of messenger RNA (mRNA) COVID-19
vaccines in children aged 5 to 11 years has been emerging. Collecting these data will inform …

Background Vaccination has been promoted to control viral transmission in response to the
coronavirus disease 2019 (COVID-19) pandemic. Cases of new-onset or exacerbation of …

BACKGROUND Little is known about the epidemiology and outcomes of neurologic
complications associated with coronavirus disease 2019 (COVID-19) in children. METHODS …

Background To date, more than 761 million confirmed SARS-CoV-2 infections have been
recorded globally, and more than half of all children are estimated to be seropositive …

Abstract Primary vaccination with mRNA-1273 (100-µg) was safe and efficacious at
preventing coronavirus disease 2019 (COVID-19) in the previously reported, blinded Part A …